Emma Duffield

12.7k citations
21 papers · 8.5k · 2 hit papers · h-index 13

Impact in

    • Lung Cancer Treatments and Mutations
    • Lung Cancer Diagnosis and Treatment
    • Gastric Cancer Management and Outcomes
  • Oncology top 0.2%
    • Lung Cancer Research Studies
    • Colorectal Cancer Treatments and Studies
    • HER2/EGFR in Cancer Research

Papers in

    • Lung Cancer Treatments and Mutations 15
    • Lung Cancer Diagnosis and Treatment 3
    • Gastric Cancer Management and Outcomes 3
    • Colorectal Cancer Treatments and Studies 9
    • Lung Cancer Research Studies 8

Emma Duffield

21 papers receiving 8.3k citations

Hit Papers

Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS) 2011 · 1.2k citations
1.2k0+5+11Years since publication2.0k4.0k6.0k

Peers

Emma Duffield
Comparison fields: 5 of 101
  • Pulmonary and Respiratory Medicine 7.2k
  • Oncology 5.7k
  • Cancer Research 2.1k
  • Molecular Biology 2.1k
  • Pathology and Forensic Medicine 442
Replace Patrapim Sunpaweravong with:
Patrapim Sunpaweravong Thailand
Jin-Ji Yang China
Haiyi Jiang Japan
Benjamin Margono Taiwan
Claire Watkins United Kingdom
Busyamas Chewaskulyong Thailand
Baohui Han China
José Rodrigues Pereira Brazil
Daniel de Castro Spain
Chun‐Ming Tsai Taiwan
Emma Duffield relative to Patrapim Sunpaweravong Thailand Patrapim Sunpaweravong's profile →
Citations per field
00.5×1.5×
Patrapim Sunpaweravong · 1×
Citations per year

Countries citing papers authored by Emma Duffield

Since Specialization
Citations

This map shows the geographic impact of Emma Duffield's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emma Duffield with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emma Duffield more than expected).

Fields of papers citing papers by Emma Duffield

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Emma Duffield. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emma Duffield. The network helps show where Emma Duffield may publish in the future.

Co-authors

The 25 scholars most cited alongside Emma Duffield, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Emma Duffield Line = papers co-authored together Emma Duffield links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 21 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Hit paper breakdown →
20096355
2
Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)
Hit paper breakdown →
20111180
3 2008176
4 2011173
5 2007161
6 2011107
7 200996
8 200995
9 201238
10 200827
11 200719
12 200715
13 200712
14 200910
15 20098
16 20115
17 20065
18 20093
19 20063
20
Oskira-3: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study Of 2 Dosing Regimens Of Fostamatinib In Rheumatoid Arthritis Patients With An Inadequate Response To a Tumor Necrosis Factor-alpha Antagonist
20131

About Emma Duffield

Emma Duffield is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Surgery, Cancer Research and Economics and Econometrics, having authored 21 papers that have together received 8.5k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (15 papers), Colorectal Cancer Treatments and Studies (9 papers), Lung Cancer Research Studies (8 papers), Lipoproteins and Cardiovascular Health (4 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (3 papers), Lung Cancer Diagnosis and Treatment (3 papers), Gastric Cancer Management and Outcomes (3 papers) and Lymphoma Diagnosis and Treatment (2 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (7.2k citations), Oncology (5.7k citations), Cancer Research (2.1k citations), Molecular Biology (2.1k citations) and Pathology and Forensic Medicine (442 citations). Emma Duffield has collaborated with scholars based in United Kingdom, Hong Kong and Japan. Frequent co-authors include Alison Armour, Nagahiro Saijo, Tony Mok, Masahiro Fukuoka, Haiyi Jiang, James Chih‐Hsin Yang, Yi‐Long Wu, Sumitra Thongprasert, Patrapim Sunpaweravong and Yukito Ichinose. Their work appears in journals such as Journal of Clinical Oncology, Journal of Thoracic Oncology, Atherosclerosis Supplements, Cardiology and New England Journal of Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact